Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,820,113 papers from all fields of science
Search
Sign In
Create Free Account
anacetrapib
A cholesteryl ester transfer protein (CETP) inhibitor with hypocholesterolemic properties. Anacetrapib reduces the transfer of cholesteryl ester from…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Anticholesteremic Agents
Oxazolidinones
MK 0859
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Impact of ADCY9 Genotype on Response to Anacetrapib
J. Hopewell
,
M. Ibrahim
,
+7 authors
R. Collins
Circulation
2019
Corpus ID: 198171513
Supplemental Digital Content is available in the text.
Review
2018
Review
2018
CETP inhibition, statins and diabetes.
P. Barter
,
B. Cochran
,
K. Rye
Atherosclerosis
2018
Corpus ID: 52919661
Review
2018
Review
2018
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk.
P. Barter
,
K. Rye
Cardiology Clinics
2018
Corpus ID: 4624052
2017
2017
CETP Inhibitors - A New Inning?
R. Hegele
New England Journal of Medicine
2017
Corpus ID: 5916754
Former baseball manager Tony La Russa once said, “Even when you have three strikes, you’re still not out. There is always…
Expand
Highly Cited
2012
Highly Cited
2012
Tangier disease: epidemiology, pathophysiology, and management.
M. Puntoni
,
F. Sbrana
,
F. Bigazzi
,
T. Sampietro
American Journal of Cardiovascular Drugs
2012
Corpus ID: 41590331
Tangier disease is one of the most severe forms of familial high-density lipoprotein (HDL) deficiency. Since its discovery it has…
Expand
2011
2011
Learning lessons from Pfizer's $800 million failure
Nature reviews. Drug discovery
2011
Corpus ID: 545018
2011
2011
Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects
Amit Garg
,
A. Maes
,
+8 authors
R. Krishna
Journal of clinical pharmacology
2011
Corpus ID: 28699763
A (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as…
Expand
Review
2011
Review
2011
Emerging therapeutic strategies to enhance HDL function
S. Redondo
,
J. Martínez-González
,
C. Urraca
,
T. Tejerina
Lipids in Health and Disease
2011
Corpus ID: 10906421
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and…
Expand
Review
2009
Review
2009
The end of the road for CETP inhibitors after torcetrapib?
T. Joy
,
R. Hegele
Current Opinion in Cardiology
2009
Corpus ID: 6965741
Purpose of review Because high-density lipoprotein cholesterol (HDL-C) levels are inversely related to cardiovascular disease…
Expand
Review
2009
Review
2009
Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
D. Masson
Current opinion in investigational drugs
2009
Corpus ID: 25756681
Anacetrapib, under development by Merck & Co Inc, is an inhibitor of the cholesterol ester transfer protein (CETP) for the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE